Novartis Ag (NVSEF) EBT (2009 - 2025)

Novartis Ag has disclosed EBT across 15 years of filings, most recently posting $4.5 billion for Q2 2025.

• EBT for Q2 2025 came in at $4.5 billion, up 17.96% year-over-year; the trailing twelve-month figure through Jun 2025 was $20.5 billion (up 67.94% YoY), and the FY2025 annual result was $16.4 billion, up 19.88% from the prior year.
• EBT came in at $4.5 billion for Q2 2025 at Novartis Ag, down from $7.0 billion in the prior quarter.
• In the past five years, EBT ranged from a high of $7.0 billion in Q4 2024 to a low of $514.0 million in Q1 2021.
• The 5-year median for EBT is $3.1 billion (2021), against an average of $3.0 billion.
• Across the five-year window, EBT surged 164.95% in 2021 and slumped 41.76% in 2022, its largest moves.
• Novartis Ag's EBT stood at $6.0 billion in 2021, then declined by 20.9% to $4.7 billion in 2022, then rose by 10.25% to $5.2 billion in 2023, then surged by 34.19% to $7.0 billion in 2024, then slumped by 34.99% to $4.5 billion in 2025.
• The last three EBT figures came in at $4.5 billion (Q2 2025), $7.0 billion (Q4 2024), and $3.8 billion (Q2 2024), per Business Quant data.